Skip to main content
Clinical Trials/NL-OMON49761
NL-OMON49761
Completed
Phase 3

Reducing health care workers absenteeism in SARS-CoV-2 pandemic by enhanced trained immune responses through Bacillus Calmette-Guérin vaccination, a randomized controlled trial. - BCG-CORONA

niversitair Medisch Centrum Utrecht0 sites1,500 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
COVID-19
Sponsor
niversitair Medisch Centrum Utrecht
Enrollment
1500
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
niversitair Medisch Centrum Utrecht

Eligibility Criteria

Inclusion Criteria

  • \* Adult (\*18 years)
  • \* Male or female
  • \* Hospital personnel taking care for patients with SARS\-CoV\-2 infection

Exclusion Criteria

  • \* Known allergy to (components of) the BCG vaccine or serious adverse events to
  • prior BCG administration
  • \* Known active or latent Mycobacterium tuberculosis or with another
  • mycobacterial species. A history with\- or a suspicion of M. tuberculosis
  • \* Fever (\>38 C) within the past 24 hours
  • \* Pregnancy
  • \* Suspicion of active viral or bacterial infection
  • \* Severely immunocompromised subjects. This exclusion category comprises: a)
  • subjects with known infection by the human immunodeficiency virus (HIV\-1\); b)
  • neutropenic subjects with less than 500 neutrophils/mm3; c) subjects with solid

Outcomes

Primary Outcomes

Not specified

Similar Trials